McDonnell Boehnen Hulbert & Berghoff LLP partner Kevin Noonan, Ph.D. is quoted in a January 3, 2018 Life Sciences IP Review article entitled, “The future of sovereign immunity deals after Allergan ruling.” Late last week, the Patent Trial and Appeal Board (PTAB) rejected a Native American tribe’s attempt to dismiss inter partes reviews (IPRs) based on the tribe’s sovereign immunity claims. view the article
